Trial Parameters
Condition Mature B-Cell Lymphoma
Sponsor Ruijin Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 320
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-09-28
Completion 2024-12
Interventions
peripheral blood collection
Brief Summary
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * 18 years or older Exclusion Criteria: * Chemotherapy before * Other tumors